Tarsus Pharmaceuticals (TARS) Competitors $57.43 -0.29 (-0.50%) Closing price 04:00 PM EasternExtended Trading$57.44 +0.01 (+0.01%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, and AXSMShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Axsome Therapeutics Tarsus Pharmaceuticals (NASDAQ:TARS) and Moderna (NASDAQ:MRNA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do analysts rate TARS or MRNA? Tarsus Pharmaceuticals currently has a consensus target price of $66.67, suggesting a potential upside of 16.08%. Moderna has a consensus target price of $42.88, suggesting a potential upside of 76.62%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Does the media refer more to TARS or MRNA? In the previous week, Moderna had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 12 mentions for Moderna and 10 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.43 beat Moderna's score of 0.73 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TARS or MRNA? Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Is TARS or MRNA more profitable? Tarsus Pharmaceuticals has a net margin of -31.13% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Moderna -94.31%-25.96%-20.09% Do insiders & institutionals hold more shares of TARS or MRNA? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, TARS or MRNA? Tarsus Pharmaceuticals has higher earnings, but lower revenue than Moderna. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M13.25-$115.55M-$2.33-24.65Moderna$3.24B2.92-$3.56B-$7.53-3.22 SummaryTarsus Pharmaceuticals and Moderna tied by winning 8 of the 16 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.44B$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E RatioN/A7.5859.1122.53Price / Sales13.25458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book9.789.9310.916.06Net Income-$115.55M-$53.38M$3.29B$266.28M7 Day Performance-1.26%0.05%0.01%-0.76%1 Month Performance37.03%7.08%7.06%3.83%1 Year Performance97.83%11.92%50.09%24.39% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals1.9951 of 5 stars$57.43-0.5%$66.67+16.1%+120.6%$2.44B$182.95M-24.6550News CoveragePositive NewsMRNAModerna4.4241 of 5 stars$24.09-1.6%$42.88+78.0%-67.0%$9.37B$3.24B-3.205,800VRNAVerona Pharma PLC American Depositary Share2.5979 of 5 stars$105.91+0.0%$109.00+2.9%+290.2%$9.16B$42.28M-106.9830News CoveragePositive NewsELANElanco Animal Health3.1154 of 5 stars$18.38-0.4%$17.33-5.7%+14.4%$9.12B$4.44B21.379,000Analyst RevisionHigh Trading VolumeROIVRoivant Sciences3.17 of 5 stars$11.93-0.1%$16.50+38.3%+7.0%$8.15B$29.05M-17.04860News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.4891 of 5 stars$37.97-0.9%$69.92+84.2%-4.3%$7.10B$11.58M-8.44250Positive NewsInsider TradeGRFSGrifols3.9365 of 5 stars$9.97+1.0%$10.30+3.3%+2.2%$6.85B$7.81B8.5223,822Positive NewsGap UpRYTMRhythm Pharmaceuticals3.3145 of 5 stars$103.15-1.0%$101.57-1.5%+121.3%$6.85B$130.13M-34.27140News CoveragePositive NewsLEGNLegend Biotech3.532 of 5 stars$34.73+1.0%$74.22+113.7%-37.3%$6.41B$627.24M-39.472,609ABVXAbivax2.4652 of 5 stars$81.03-0.7%$92.33+13.9%+574.1%$6.12BN/A0.0061News CoveragePositive NewsShort Interest ↓AXSMAxsome Therapeutics4.7797 of 5 stars$121.28-0.4%$178.00+46.8%+36.1%$6.05B$385.69M-23.92380News CoveragePositive NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Abivax Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts